The Hidden Complexity in the Development of Your mRNA Process
Behind the perceived simplicity of mRNA process development, there are many challenges, such as the high cost of raw material, variable target doses, limited productivity, and diverse RNA modalities.
This roundtable explores challenges around mRNA workflow and how characterization models can enable the prediction of process outcomes at early stages. Attendees will also learn how to ensure that mRNA drugs meet purity requirements.
What Will You Learn:
- Discover the challenges of mRNA process development and how mRNA process intensification can optimize cost and productivity
- Learn characterization strategies and models for predicting process outcomes at early stages
- Understand how to purify new RNA therapeutics, including saRNA and circRNA
Meet Our Experts:
Piergiuseppe Nestola, PhD
Manager of Process Technology Consultants
Piergiuseppe Nestola is Manager of Process Technology Consultants at Sartorius, where he is responsible for providing scientific, technological, and process leadership in the field of viral-based therapeutics. He holds a PhD in chemical and biochemical engineering from Universidade Nova de Lisboa (PT), where he developed virus purification processes for vaccines and gene therapies.
Tomas Kostelec
Product Manager mRNA | pDNA
Tomas Kostelec has completed his Master’s in organic chemistry in Chemistry at University College London, with a focus on multimodal contrast agents for medical imaging. He joined BIA Separations, now part of Sartorius in 2016 as analytical scientist to support contract work and development activities for AAV, influenza, and other viruses. He is currently Product Manager for mRNA at Sartorius, his area of interest includes purification and analytics of mRNA.
Zoltán Kis
Lecturer
Zoltán Kis is a Lecturer at the Department of Chemical and Biological Engineering at The University of Sheffield, and an Honorary Lecturer at the Department of Chemical Engineering, Imperial College London, where he earned his PhD in Bioengineering. He leads a multidisciplinary team that is innovating and digitalizing RNA vaccine and therapeutics production platform technologies.